Intellia Therapeutics, Inc.
12.21USD
-0.5300 (-4.16%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 15 | 23 | 14 | 14 | 17 | 13 | 9 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -113 | -101 | -99 | -111 | -110 | -121 | -136 | -145 |
| Net Income | -107 | -96 | -96 | -101 | -101 | -114 | -129 | -136 |
| EPS (Diluted) | $-0.80 | $-0.81 | $-0.82 | $-0.92 | $-0.98 | $-1.10 | $-1.26 | $-1.34 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)